Description
Daonil Tablet is an anti-diabetic medicine manufactured by Sanofi India Ltd. It contains Glibenclamide (5mg), which belongs to the class of medicines known as sulfonylureas. This medicine works by stimulating the pancreas to release more insulin, which helps lower blood glucose levels. It is commonly prescribed for patients with type 2 diabetes mellitus (non-insulin-dependent diabetes) when diet and exercise alone are not enough to control blood sugar.
By keeping blood sugar levels under control, Daonil Tablet helps prevent or reduce the risk of serious long-term complications of diabetes, such as kidney damage, eye problems, nerve damage, heart disease, and stroke. For best results, it should be taken in combination with a proper diet, regular exercise, and lifestyle modifications as advised by the doctor.
Uses
-
Controls high blood sugar levels in type 2 diabetes mellitus
-
Helps in preventing diabetes-related complications like kidney damage, blindness, nerve problems, and heart disease
-
Can be used alone or with other anti-diabetic medicines to achieve better blood sugar control
Dosage
-
The dose should be taken exactly as prescribed by the doctor
-
Usually taken once daily with breakfast or the first main meal of the day
-
Do not skip meals while taking this medicine, as it can cause low blood sugar (hypoglycemia)
-
The dose may be adjusted based on blood sugar monitoring and individual response
Side Effects
-
Low blood sugar (hypoglycemia): sweating, dizziness, hunger, shakiness
-
Nausea, stomach upset
-
Weight gain
-
Allergic skin reactions (rare)
Precautions
-
Regular monitoring of blood glucose is necessary
-
Avoid alcohol as it can increase the risk of hypoglycemia
-
Not suitable for patients with type 1 diabetes or diabetic ketoacidosis
-
Use with caution in patients with kidney or liver disease
-
Pregnant or breastfeeding women should consult a doctor before taking this medicine
-
Always inform your doctor about other medicines being used to avoid harmful drug interactions







Leave a Reply